return to press releases

February 3, 2003

AnVil to Work With the National Cancer Institute in Analyzing Genetic Data for Lung Cancer Research

Pioneer in life sciences discovery works with public health agency in search for genetic predictors of lung cancer.

Burlington, MA - February 3, 2003 - In the quest to discover better predictive models for cancer diagnostics and treatment, life sciences pioneer AnVil, Inc. announced an agreement today with the National Cancer Institute (NCI), a component of the National Institutes of Health, to analyze NCI lung tumor databases in search of data that can be used to discover gene markers for lung cancer, diagnostics, treatments and therapy.

AnVil will use its domain expertise and analysis and visualization services and technologies to explore NCI gene expression data in order to predict which genes may be specifically associated with lung tumors or normal lung tissue. AnVil will provide NCI with more effective information to help research for new cancer targets and therapies.

The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.

Dr. Richard Gill, President and CEO of AnVil, said, "We're very pleased to continue working with the National Cancer Institute database, from which we were able to derive very strong models for genetic predictors in recent work with NCI. We look forward to taking our predictive models to the next level, and continue to help further cancer research by generating more insightful data and analysis of the disease."

About AnVil
AnVil is a pioneering life sciences discovery company that turns data into knowledge. AnVil partners with life sciences, pharmaceutical, biotechnology, and healthcare companies, enabling them to see and interpret multiple data sets in integrated, information-rich views. This approach turns data into decision-quality information, generating informed decisions faster and more accurately. AnVil's combination of scientific perspective, expertise and high-dimensional technology uncovers the limitless possibilities within complex data sets.

This document contains forward-looking statements. Any statements contained in this press release that do not describe historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. The factors that could cause actual results to differ materially from current expectations include the following: the timing and results of the Company's product development efforts, the ability to successfully complete additional development efforts with respect to the Company's products and product candidates, uncertainties regarding clinical studies, the timing and results of FDA actions, uncertainties relating to patents and proprietary rights and other risks identified in Company's Securities and Exchange Commission filings. The Company cautions readers not to place undue reliance on any forward-looking statements that speak only as of the date they are made. Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

AnVil is based in Burlington, Massachusetts. For more information, visit www.anvilinfo.com, or call 1-781-272-1600. E-mail inquiries should be sent to: William Wiegler at wwiegler@anvilinfo.com.

Copyright (c) 2003 AnVil, Inc. All rights reserved.

back to top